Mr. Papa concluded, "We are very impressed with Paddock's solid foundation and growth over the past 30 years. Bruce Paddock and his team, led by CEO Michael Graves, have built a company focused on bringing high quality products quickly to market, backed by state-of-the-art manufacturing. I am confident that this strategic acquisition will help to further grow our existing Rx business and continue to add value for our shareholders."
Conference call information
Perrigo will host a conference call for investors and analysts at 8:30 a.m. (EST) on Thursday, January 20. The conference call will be available live via webcast to interested parties on the Perrigo website http://www.perrigo.com or by phone 877-248-9413, International 973-582-2737 and reference ID# 38879007. A taped replay of the call will be available beginning at approximately 2:00 p.m. (EST) Thursday, January 20, until midnight , Thursday, February 3, 2011. To listen to the replay, call 800-642-1687, International 706-645-9291, access code 38879007.
Perrigo's financial advisor is Morgan Stanley, and its legal advisor is Morgan, Lewis & Bockius LLP. Paddock Laboratories' financial advisors are Jefferies & Company and Greene Holcomb & Fisher, and its legal advisor is Orrick, Herrington & Sutcliffe, LLP.
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kin
|SOURCE Perrigo Company|
Copyright©2010 PR Newswire.
All rights reserved